Cumulus Neuroscience Showcases Innovative Data at Major Neuroscience Conferences
Cumulus Neuroscience Showcases Innovative Data at Major Neuroscience Conferences
Cumulus Neuroscience, a leading global digital health company, is making waves in the field of neuroscience clinical trials. The company recently presented important findings at the International Society for CNS Clinical Trials and Methodology Autumn Conference and the 38th European College of Neuropsychopharmacology Congress held in Amsterdam, Netherlands. These gatherings are pivotal platforms for researchers and professionals focused on advancing the understanding and treatment of central nervous system disorders.
One of the main challenges in conducting clinical trials for conditions affecting the central nervous system (CNS), such as Major Depressive Disorder (MDD) and Alzheimer’s Disease (AD), is their lengthy duration, high costs, and participant burden. Cumulus has addressed these challenges with its NeuLogiq® Platform, developed in collaboration with top-tier biopharma companies. This innovative platform is designed to enhance the collection of clinical quality data through frequent digital measurements, either in clinical setups or at home. The capabilities offered by NeuLogiq help sponsors gather critical insights that promote earlier and more informed decision-making, ultimately leading to significant cost savings.
At the ECNP, Cumulus presented a poster titled, "Deploying User-Friendly Portable EEG to Measure Response to a Novel Antidepressant with Resting and Task-Driven Neurophysiological Endpoints". This poster detailed interim findings from a Phase 1b study conducted alongside Delix Therapeutics, focusing on a novel neuroplasticity drug, DLX-001. The study aims to provide early evidence concerning the drug's effects on neural targets and cognitive acuity among patients suffering from MDD. Utilizing the NeuLogiq Platform, the research team was able to conduct high-frequency assessments concerning cognitive and neurophysiological changes in real-time.
Dr. Aaron Koenig, CMO at Delix Therapeutics, expressed enthusiasm for the results, noting how the NeuLogiq Platform supported their ability to assess neuroplastic effects and cognitive engagement throughout the study. The goal is to complement traditional methods with low-burden markers that could streamline and enhance clinical program development.
Scheduled for October 21st, Dr. Koenig and Dr. Brian Murphy, CSO of Cumulus, will lead a webinar titled "Neuropsychiatry Clinical Trials Evolving with Portable EEG and Digital Endpoints", where they’ll delve deeper into the findings surrounding the Delix DLX-001 Phase 1b study.
Furthermore, Cumulus shared additional findings in a poster titled "Scalable Digital Endpoints Improve Sensitivity to Cognitive Change and Can Drive Efficiencies in CNS Clinical Trials". This study analyzed data from Cumulus’s flagship CNS-101 study, which monitored 59 patients with mild dementia and 60 age-matched controls over 12 months. The results indicated that home-based digital cognitive assessments were significantly more sensitive to cognitive changes than existing benchmarks, like the ADAS-Cog 13. Remarkably, the findings showcased that smaller cohorts powered by digital endpoints could yield equivalent or even greater insights compared to larger traditional trial designs.
A third poster presented at the ISCTM was titled "Streamlining CNS Clinical Research with Digital Endpoints - the Trade-off Between Shorter Versus Smaller Trial Designs". This presentation focused on modeling substantial cost and time savings associated with reducing participant numbers instead of trial duration in Phase II studies related to MDD and Alzheimer’s. The analysis, covering 132 industry trials, suggests considerable efficiency gains and accelerated timelines by employing smaller cohorts in conjunction with digital endpoints.
Both Dr. Murphy and Dr. Koenig underscored the potential of using NeuLogiq in fostering new approaches that can significantly enhance and accelerate clinical trials. By combining remote and interactive monitoring capabilities across various dimensions of brain function, Cumulus is poised to optimize CNS clinical research for both industry partners and patients alike.
Cumulus Neuroscience remains committed to creating actionable insights necessary for improving both diagnostics and management strategies for CNS disorders. Their work harnesses AI-driven analytics to simplify complex clinical trials, ensuring vital data is captured seamlessly over time.
Conclusion
The advancements showcased by Cumulus Neuroscience at these notable conferences emphasize their commitment to transforming neuroscience research. By leveraging innovative tools like NeuLogiq, they are paving the way for improved clinical outcomes, ultimately benefiting patients and enhancing the overall landscape of CNS trials. To learn more about Cumulus and its endeavors, visit Cumulus Neuroscience.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.